Risedronate in the treatment of Murine Chagas' disease

Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology research (1987) 2005-06, Vol.96 (3), p.184-187
Main Authors: BOUZAHZAH, Boumediene, JELICKS, Linda A, MORRIS, Stephen A, WEISS, Louis M, TANOWITZ, Herbert B
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Chagas Cardiomyopathy - drug therapy
Chagas Cardiomyopathy - parasitology
Chagas Cardiomyopathy - pathology
Chagas Disease - drug therapy
Chagas Disease - parasitology
Chagas Disease - pathology
Disease Models, Animal
Etidronic Acid - administration & dosage
Etidronic Acid - analogs & derivatives
Etidronic Acid - pharmacology
Etidronic Acid - therapeutic use
Fundamental and applied biological sciences. Psychology
General aspects
General aspects and techniques. Study of several systematic groups. Models
Invertebrates
Mice
Mice, Inbred C57BL
Myocardium - pathology
Risedronate Sodium
Survival Analysis
Trypanocidal Agents - administration & dosage
Trypanocidal Agents - pharmacology
Trypanocidal Agents - therapeutic use
Trypanosoma cruzi - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.
ISSN:0932-0113
1432-1955
DOI:10.1007/s00436-005-1331-9